Interferon Beta
Information about Interferon Beta[edit source]
Interferon beta (ß-1a and ß-1b) is a cytokine and belongs to a group of naturally occurring proteins which interact with cell surface receptors to produce intracellular antiviral, anti-proliferative, and immuno-modulatory effects.
Liver safety of Interferon Beta[edit source]
Interferon beta is used commonly to prevent relapses in multiple sclerosis. Interferon beta is a well known cause of mild hepatic injury that occasionally can lead to severe liver injury with jaundice.
Mechanism of action of Interferon Beta[edit source]
Interferon (in" ter feer' on) beta is a type I interferon produced by fibroblasts and macrophages in response to viral infection and antigenic stimuli. Interferon beta is structurally and antigenically distinct from interferon alfa, but they share the same cell surface receptors. Despite having a common receptor, the two interferons have different intracellular effects, acting through related but different pathways to trigger changes in gene expression that modulate inate and adaptive immune responses and antiviral pathways. Interferon beta was developed largely as an immunomodulatory agent and showed evidence of benefit in relapsing multiple sclerosis for which it was first approved for use in the United States in 1993. Its major indication is to reduce the frequency of clinical exacerbations. Currently, five forms of interferon beta are available:
FDA approval information for Interferon Beta[edit source]
Betaseron – interferon ß-1b, subcutaneous injection (250 mcg) every other day. Approved 1993. Extavia – interferon ß-1b, subcutaneous injection (250 mcg) every other day. Approved 1993 Avonex – interferon ß-1a, intramuscular injection (30 mcg) once weekly. Approved 1996. Rebif – interferon ß-1a, subcutaneous injection (8.8 mcg, 22 mcg, 44 mcg) thrice weekly. Approved 2003. Plegridy – peginterferon ß-1a, subcutaneous injection (63, 94, 125 mcg) every 14 days. Approved 2014. The various forms of beta interferon are provided as a lyophilized powder for reconstition or as a solution in single dose vials or in preflilled syringes, pens or autoinjectors. All five forms of beta interferon are produced by recombinant DNA techniques. They differ in specific activity and pharmacokinetics and thus are used in different doses and regimens. Peginterferon ß-1a consists of recombinant beta interferon covalently linked to polyethylene glycol which makes it a larger protein molecule with a longer half-life and duration of action. Therapy is routinely given long term.
Side effects of Interferon Beta[edit source]
Typical side effects include fatigue, muscle aches, headache, depression, fever and mild bone marrow suppression. Severe adverse events reported with use of beta interferon include hypersensitivity reactions, thrombotic microangiopathy, severe depression, suicidal thoughts and behaviors and autoimmune disorders.
Interferon Beta Resources | ||
---|---|---|
|
|
Disease modifying agents
- Alemtuzumab
- Dimethyl Fumarate
- Fingolimod
- Glatiramer Acetate
- Interferon Beta
- Interferon Beta-1a
- Interferon Beta-1b
- Peginterferon Beta-1a
- Mitoxantrone
- Natalizumab
- Ocrelizumab
- Teriflunomide
Symptomatic Therapies
Interferon Beta Resources | ||
---|---|---|
|
|
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD